America’s fisheries are among the world’s richest in abundance and diversity. They provide scientific, aesthetic, recreational, commercial, subsistence, cultural, social, and economic benefits. FAC leads aquatic resource management for the Service and strives to invest its resources in the nation’s highest priority aquatic conservation and water-based recreational needs. Fish health is a critical component of healthy fisheries and core to the work of the Fish and Aquatic Conservation Program.
The Aquatic Animal Drug Approval Partnership (AADAP) program is part of the Fish and Aquatic Conservation fish health work. It is the only program in the United States singularly dedicated to obtaining U.S. Food and Drug Administration (FDA) approval of new medications needed for use in fish culture and fisheries management. Since the late 1990’s, AADAP has contributed to virtually every new fish medication approved by the FDA. Ultimately, the AADAP program allows fisheries professionals to more effectively and efficiently rear and manage a variety of fish species to meet production goals, stock healthy fish, and maintain a healthy environment.
AADAP is planning to co-host a special session with the AFWA Drug Approval Working Group (DAWG) at Aquaculture America 2020, to be held in Honolulu, HI from February 9th-12th, 2020. The session title is "Aquaculture Drug Updates". The date/time for this session is still TBD, but more information will be posted soon.
The 26th Annual Aquaculture Drug Approval Coordination Workshop is scheduled for July 27th-30th, 2020 in Bozeman, MT. Stay tuned to the AADAP website and monthly AADAP Updates for more details later this winter!
AADAP is on the lookout for facilities with the following conditions/species combinations in which to conduct efficacy studies:
If you know of any facilities with these conditions, please have them contact AADAP directly. Thank you!